Eli Lilly and Company has announced that Anne White, executive vice president and president of Lilly Neuroscience, will retire at the end of 2025 after more than 30 years with the company.
White will remain in her role, and as a member of the executive committee, until her retirement on 31 December. A search for her successor is currently under way.
During her tenure, White played a leading role in the launch of Lilly’s first Alzheimer’s treatment and previously headed the company’s oncology division, where she oversaw the development of therapeutics and the acquisition of Loxo Oncology. Under her leadership, Lilly has expanded its neuroscience portfolio to include treatments for neurodegeneration, pain, substance use disorders and psychiatric conditions.
David A Ricks, Lilly’s chair and chief executive, said: “Anne’s career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases affecting patients globally. She led the global launch of our first ever Alzheimer’s treatment.”
White has also been recognised for her advocacy of diversity and inclusion. She sits on the board of Lambda Legal and has been named among the Most Influential Women Executives in Corporate America by WomenInc, as well as a Woman of Influence by the Indianapolis Business Journal – both US business media platforms.
